PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders

PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders

Adenosine A2A receptor (A2AR) antagonists have emerged as complementary non-dopaminergic drugs to alleviate Parkinson’s disease (PD) symptomatology. Here, we characterize a novel non-xhantine non-furan A2AR antagonist, PBF509, as a potential pro-dopaminergic drug for PD management. First, PBF509 was...

Full description

Bibliographic Details
Main Authors: Fabiana Núñez, Jaume Taura, Juan Camacho, Marc López-Cano, Víctor Fernández-Dueñas, Naomi Castro, Julio Castro, Francisco Ciruela
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Pharmacology
Subjects:
PBF509
Parkinson’s disease
adenosine A2A receptor
catalepsy
label-free
tremor
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01200/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01200/full

Similar Items